Doron Lipson

23.8k citations

133 papers · 10.3k indexed · 4 hit papers · h-index 49

Molecular Biology top 1%
Oncology top 0.5%
Cancer Research top 0.5%
Pulmonary and Respiratory Medicine top 0.5%
Genetics top 1%

Co-authors: Zohar Yakhini Eran Eden Roy Navon Israel Steinfeld Vincent A. Miller Jeffrey S. Ross Philip J. Stephens Roman Yelensky
Topics: Cancer Genomics and Diagnostics (60 papers)Lung Cancer Treatments and Mutations (27 papers)Genetic factors in colorectal cancer (12 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Nature Science Cell
Partner nations: United States Israel South Korea

In The Last Decade

Doron Lipson

128 papers receiving 10.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists

2009 2.4k citations Doron Lipson, Zohar Yakhini et al. profile →
Two-State Allosteric Behavior in a Single-Domain Signaling Protein

2001 508 citations Doron Lipson et al. profile →
Discovering Motifs in Ranked Lists of DNA Sequences

2007 503 citations Doron Lipson, Zohar Yakhini et al. PLoS Computational Biology profile →
Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq

2022 253 citations Joseph M. Replogle, Reuben A. Saunders et al. Cell profile →

Peers

Countries citing papers authored by Doron Lipson

Since Specialization

Citations

This map shows the geographic impact of Doron Lipson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Doron Lipson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Doron Lipson more than expected).

Fields of papers citing papers by Doron Lipson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Doron Lipson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Doron Lipson. The network helps show where Doron Lipson may publish in the future.

Co-authorship network of co-authors of Doron Lipson

This figure shows the co-authorship network connecting the top 25 collaborators of Doron Lipson. A scholar is included among the top collaborators of Doron Lipson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Doron Lipson. Doron Lipson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Systematic reconstruction of molecular pathway signatures using scalable single-cell perturbation screens 2025 ·Nature Cell Biology ·Longda Jiang,(unknown),Efthymia Papalexi,(unknown),Hans‐Hermann Wessels,(unknown),Nika Iremadze,Gila Lithwick‐Yanai,Doron Lipson,Rahul Satija	5
2	Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seqbreakdown → 2022 ·Cell ·Joseph M. Replogle,Reuben A. Saunders,Angela N. Pogson,Jeffrey A. Hussmann,Alexander LeNail,Alina Guna,Lauren G. Mascibroda,Eric J. Wagner,Karen Adelman,Gila Lithwick‐Yanai,Nika Iremadze,Florian C. Oberstrass,Doron Lipson,Jessica L. Bonnar,Marco Jost,Thomas M. Norman,Jonathan S. Weissman	253
3	Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization 2019 ·Lung Cancer ·Luna Kadouri,Yakir Rottenberg,Aviad Zick,Tamar Hamburger,Doron Lipson,Tamar Peretz,Hovav Nechushtan	23
4	A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal 2018 ·PLoS Computational Biology ·James Sun,Yuting He,Eric M. Sanford,Meagan Montesion,Garrett M. Frampton,Stéphane Vignot,Jean‐Charles Soria,Jeffrey S. Ross,Vincent A. Miller,Phil Stephens,Doron Lipson,Roman Yelensky	177
5	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis 2017 ·Cancer Research ·Ryan J. Hartmaier,Lee A. Albacker,Juliann Chmielecki,Mark Bailey,Jie He,Michael E. Goldberg,Shakti Ramkissoon,James Suh,Julia A. Elvin,(unknown),Garrett M. Frampton,Jeffrey S. Ross,Vincent A. Miller,Philip J. Stephens,Doron Lipson	85
6	Analytic validation of a next generation sequencing assay to identify tumor mutational burden from blood (bTMB) to support investigation of an anti-PD-L1 agent, atezolizumab, in a first line non-small cell lung cancer trial (BFAST) 2017 ·Annals of Oncology ·David Fabrizio,Christine M. Malboeuf,Daniel S. Lieber,Shan Zhong,Jianzhong He,Elizabeth C. White,Michael J. Coyne,Jacob Silterra,Tina Brennan,Jun Ma,Mark Kennedy,Erica Schleifman,Sarah Paul,(unknown),David S. Shames,Craig Cummings,Eric Peters,Marcin Kowanetz,Doron Lipson,Geoff Otto	14
7	Recurrent Copy Number Variants Are Highly Prevalent in Acute Myeloid Leukemia 2017 ·Blood ·Katherine Tarlock,Yuting He,James Sun,Rhonda E. Ries,Eric A. Severson,Mark Bailey,Samantha Morley,Sohail Balasubramanian,Rachel Erlich,Doron Lipson,Geoff Otto,(unknown),Jeffrey S. Ross,Tariq I. Mughal,Phil Stephens,Vincent A. Miller,Soheil Meshinchi,Jie He	1
8	Analytic validation of a clinical circulating tumor DNA assay for patients with solid tumors 2016 ·Annals of Oncology ·Philip J. Stephens,Travis Clark,Mark Kennedy,Jiankui He,Graeme P. Young,(unknown),Mark Coyne,(unknown),Lauren Young,Shan Zhong,(unknown),Bernard J. Fendler,V.A. Miller,Erica Schleifman,Eric Peters,Gordon Otto,Doron Lipson,Jeffrey S. Ross	2
9	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences 2015 ·The Oncologist ·Kai Wang,Adrienne Johnson,Siraj M. Ali,Samuel J. Klempner,Tanios Bekaii‐Saab,Jeffrey Vacirca,Depinder Khaira,Roman Yelensky,Juliann Chmielecki,Julia A. Elvin,Doron Lipson,Vincent A. Miller,Philip J. Stephens,Jeffrey S. Ross	75
10	EGFR Kinase Domain Duplication ( EGFR -KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib 2015 ·Cancer Discovery ·Jean‐Nicolas Gallant,Jonathan H. Sheehan,Timothy M. Shaver,Mark Bailey,Doron Lipson,Raghu Chandramohan,Monica Red Brewer,Sally J. York,Mark G. Kris,Jennifer A. Pietenpol,Marc Ladanyi,Vincent A. Miller,Siraj M. Ali,Jens Meiler,Christine M. Lovly	81
11	Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches 2015 ·Clinical Cancer Research ·Alexander Drilon,Lu Wang,Maria E. Arcila,Sohail Balasubramanian,Joel Greenbowe,Jeffrey S. Ross,Phil Stephens,Doron Lipson,Vincent A. Miller,Mark G. Kris,Marc Ladanyi,Naiyer A. Rizvi	202
12	A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy 2015 ·OncoTargets and Therapy ·Caitlin McMahon,Casey Williams,Brian Leyland‐Jones,Siraj M. Ali,(unknown),Kirstin Williams,(unknown),(unknown),Roman Yelensky,Thomas J. George,Julia A. Elvin,Salil Soman,Doron Lipson,Juliann Chmielecki,Deborah Morosini,Vincent A. Miller,Philip J. Stephens,Jeffrey S. Ross	7
13	Identification of Recurrent FGFR3–TACC3 Fusion Oncogenes from Lung Adenocarcinoma 2014 ·Clinical Cancer Research ·Marzia Capelletti,Michael Dodge,Dalia Ercan,Peter S. Hammerman,Seung-Il Park,Young Tae Kim,Hidefumi Sasaki,David M. Jablons,Doron Lipson,Lauren Young,Phil Stephens,Vincent A. Miller,Neal I. Lindeman,Kiara J. Munir,William G. Richards,Pasi A. Jänne	79
14	Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions 2014 ·Cancer Discovery ·Christine M. Lovly,Abha A. Gupta,Doron Lipson,Geoff Otto,Tina Brennan,Catherine T. Chung,Scott C. Borinstein,Jeffrey S. Ross,Philip J. Stephens,Vincent A. Miller,Cheryl M. Coffin	303
15	Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes 2014 ·Cancer Discovery ·Juliann Chmielecki,Katherine E. Hutchinson,Garrett M. Frampton,Zachary R. Chalmers,Adrienne Johnson,Chanjuan Shi,Julia A. Elvin,Siraj M. Ali,Jeffrey S. Ross,Olca Baştürk,Sohail Balasubramanian,Doron Lipson,Roman Yelensky,William Pao,Vincent A. Miller,David S. Klimstra,Philip J. Stephens	126
16	Response of an ERBB2-Mutated Inflammatory Breast Carcinoma to Human Epidermal Growth Factor Receptor 2–Targeted Therapy 2014 ·Journal of Clinical Oncology ·Siraj M. Ali,R. Katherine Alpaugh,Sean R. Downing,Philip J. Stephens,Jian Yu,Hong Wu,Jamie Buell,Vincent A. Miller,Doron Lipson,Gary A. Palmer,Jeffrey S. Ross,Massimo Cristofanilli	40
17	Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin 2014 ·The Oncologist ·Juliann Chmielecki,Jeffrey S. Ross,Kai Wang,Garrett M. Frampton,Gary A. Palmer,Siraj M. Ali,Norma Alonzo Palma,Deborah Morosini,Vincent A. Miller,Roman Yelensky,Doron Lipson,Philip J. Stephens	75
18	BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition 2013 ·Clinical Cancer Research ·Katherine E. Hutchinson,Doron Lipson,Philip J. Stephens,Geoff Otto,Brian D. Lehmann,Pamela L. Lyle,Cindy L. Vnencak‐Jones,Jeffrey S. Ross,Jennifer A. Pietenpol,Jeffrey A. Sosman,Igor Puzanov,Vincent A. Miller,William Pao	124
19	Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell Lung Cancer 2012 ·Journal of Thoracic Oncology ·Nir Peled,Gary A. Palmer,Fred R. Hirsch,Murry W. Wynes,Maya Ilouze,Marileila Varella‐Garcia,Lior Soussan‐Gutman,Geoff Otto,Philip J. Stephens,Jeffrey S. Ross,Maureen Cronin,Doron Lipson,Vincent A. Miller	102
20	Global organization of replication time zones of the mouse genome 2008 ·Genome Research ·Shlomit Farkash-Amar,Doron Lipson,Andreas Polten,Alon Goren,Charles E. Helmstetter,Zohar Yakhini,Itamar Simon	132

About Doron Lipson

Doron Lipson is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 133 papers that have together received 10.3k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (60 papers), Lung Cancer Treatments and Mutations (27 papers) and Genetic factors in colorectal cancer (12 papers). The work is most often cited by research in Cancer Research (2.5k citations), Oncology (2.7k citations) and Molecular Biology (5.8k citations). Doron Lipson has collaborated with scholars based in United States, Israel and South Korea. Frequent co-authors include Zohar Yakhini, Eran Eden, Roy Navon, Israel Steinfeld, Vincent A. Miller, Jeffrey S. Ross, Philip J. Stephens, Roman Yelensky, Siraj M. Ali and Dorothee Kern. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact